Sionna Therapeutics, Inc. (SION)

NGM – Цена в реальном времени. Валюта: USD

42.18

-0.59 (-1.38%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

42.18

-0.00 (-0.00%)

После закрытия: Jun 26, 2026, 4:36 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Sionna Therapeutics, Inc. (SION)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Sionna Therapeutics, Inc. (SION)

Sionna Therapeutics, Inc. (SION) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Sionna Therapeutics to Participate in Upcoming June 2026 Investor Conferences

Sionna Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

Sionna Therapeutics Reports First Quarter 2026 Financial Results

Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis

Sionna Therapeutics to Participate in the Raymond James 2026 Biotech Innovation Symposium

Sionna Chief Legal Officer Cashed Out Her Shares. Her Options Are Another Story

Видео

No Data

Пресс-релизы

Sionna Therapeutics Reports First Quarter 2026 Financial Results

Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis

Sionna Therapeutics to Participate in the Raymond James 2026 Biotech Innovation Symposium

Sionna Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

Search stocks

Sionna Therapeutics, Inc. (SION)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Sionna Therapeutics, Inc. (SION)

Sionna Therapeutics, Inc. (SION) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Sionna Therapeutics to Participate in Upcoming June 2026 Investor Conferences

Sionna Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

Sionna Therapeutics Reports First Quarter 2026 Financial Results

Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis

Sionna Therapeutics to Participate in the Raymond James 2026 Biotech Innovation Symposium

Sionna Chief Legal Officer Cashed Out Her Shares. Her Options Are Another Story

Видео

No Data

Пресс-релизы

Sionna Therapeutics Reports First Quarter 2026 Financial Results

Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis

Sionna Therapeutics to Participate in the Raymond James 2026 Biotech Innovation Symposium

Sionna Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results